Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
    • State Disclosures
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Cocaine Intoxication
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-801
      • TNX-1800
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Fact Sheet
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Form 8937
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Tonix in the News
  • Tonix Sponsored News
  • IR Events
  • Email Alerts
  • Op-Eds
Jan 24, 2017 7:00am EST

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13

Jan 10, 2017 1:00pm EST

Tonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference

Jan 3, 2017 7:00am EST

Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at 9th Annual Biotech Showcase Conference

Dec 19, 2016 7:00am EST

Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA

Dec 8, 2016 7:00am EST

Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)

Dec 2, 2016 7:21am EST

Tonix Pharmaceuticals to Present Clinical Data at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Nov 30, 2016 7:00am EST

Tonix Pharmaceuticals to Present at 9th Annual LD Micro Main Event Investor Conference

Nov 10, 2016 4:30pm EST

Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results

Nov 10, 2016 7:00am EST

Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD

Nov 7, 2016 7:00am EST

Tonix Pharmaceuticals to Present Clinical Data at the International Society for Traumatic Stress Studies (ISTSS) 32nd Annual Meeting

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • Page 51
  • Page 52
  • Page 53
  • Page 54
  • Page 55
  • Page 56
  • …
  • …Page 69
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2025 Tonix Pharmaceuticals Holding Corp.